Kornimate/medical-research-clean huggingface dataset:
effects of structured exercise program in bilateral vestibular hypofunction

Conditions: Bilateral Vestibular Hypofunction

Summary: background: the vestibular rehabilitation is an exercise-based method, aiming to maximize central nervous system(cns) compensation at vestibular nuclear and other cns levels for vestibular pathology. a minimal number of studies have documented the impact of vestibular rehabilitation on the recovery rate of patients with bilateral vestibular hypofunction(bvh). objective: the purpose of this study was to investigate the effectiveness of structured vestibular rehabilitation (vr) programs on severity of dizziness, kinesiophobia, balance, fatigue, quality of sleep, activities of daily living( adl) and quality of life(qol) in subjects with chronic bvh. method: twenty-five participants diagnosed with bvh were included in the study. a structured vr program was applied in 50-minute sessions once a week and as a home exercise program 3 days a week over 8 weeks. participants were evaluated for severity of dizziness with the visual analog scale (vas), for kinesiophobia with the tampa scale of kinesiophobia (tsk), for balance with the semitandem, tandem, and standing tests, for quality of sleep with the pittsburgh sleep quality index (psqi), for adl with the vestibular disorders activities of daily life (vadl), for qol with dizziness handicap inventory (dhi) and for fatigue with the fatigue severity scale (fss) at the baseline (t0), at 4th week (t1), 8th week (t2), and 20th week (t3) after study started.


Eligibility criteria:
inclusion criteria: * being between 20-80 years old * diagnosed with bilateral peripheral vestibular hypofunction by videonystagmography * have symptoms for more than three months from onset of illness exclusion criteria: * having no symptoms of bilateral peripheral vestibular hypofunction * having meniere's disease, vestibular migraine and other undulating vestibular disorders, cognitive, visual, neurological or general motor impairment * having previously received vestibular rehabilitation

Keywords: bilateral vestibular hypofunction dizziness kinesiophobia balance quality of sleep quality of life structured exercise
testing the effect of whole-wheat sourdough bread compared to white bread on healthy individuals

Conditions: Dietary Modification; Bread; Gastrointestinal Microbiome; Hematologic Tests; Body Weight Changes

Summary: bread is the most common grain product in the world, with consumption surpassing 3 billion individuals per year. sourdough whole-grain bread is considered a healthy alternative to white, refined-wheat bread. this cross-over study will test the effect of consumption of sourdough bread compared to white bread following a short dietary intervention period (one week) on multiple clinical parameters and gut microbiota.


Eligibility criteria:
inclusion criteria: * able to provide and signed informed consent form * over 18 years * not in active military service * ability to technically operate a glucometer exclusion criteria: * prediagnosed type i / type ii diabetes mellitus * pregnancy * usage of antibiotics within three months prior to participation * chronically active inflammatory or neoplastic disease in the three years prior to enrollment * skin disease, including contact dermatitis, precluding proper attachment of the continuous glucose monitor

Keywords: bread microbiome blood tests sourdough bread dietary intervention
the use of directed probiotics in me/cfs: myalgic encephalomyelitis/chronic fatigue syndrome

Conditions: ME/CFS; IBS - Irritable Bowel Syndrome

Summary: this clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the institute of medicine (canadian consensus criteria) case definition for me/cfs and who may or may not be diagnosed with irritable bowel syndrome (ibs). the main questions it aims to answer are: * how effective is the usage of the i3.1 probiotic to reduce gastrointestinal (gi) inflammation and normalize the gi and systemic/brain interface? * how well is it working on ibs severity? the study sample is 100 male and female participants aged 45 to 70 years with me/cfs (per the canadian consensus criteria); one-half of the participants will have co-morbid ibs (per rome iv criteria). participants will receive an i3.1 or a placebo and be assessed at baseline, at eight weeks, and at 12 weeks (four weeks post-treatment completion).

this single-site comparison study will be performed on 100 participants, 45 to 70 years of age, who meet the institute of medicine (canadian consensus criteria) case definition for me/cfs and who may or may not be diagnosed with the irritable bowel syndrome (ibs), according to the rome iv criteria. in this study, we will evaluate using the i3.1 probiotic compared to placebo. this is a randomized, placebo-controlled trial with four study arms that will include 25 participants per arm: individuals with me/cfs with and without ibs, who will take either the active medication i3.1 or placebo.

Eligibility criteria:
inclusion criteria: eligible if all of the following apply: * meets iom me/cfs case definition criteria, * co-morbid ibs: meets romeiv criteria for alternating or diarrhea-predominant ibs as reported during screening (technically diagnosed by a physician), * able to provide consent to study, * patients of childbearing potential must practice effective contraception during the study and be willing to continue contraception for at least six months after the intervention, * agrees to participate in online surveys and follow-up visits. exclusion criteria: ineligible if any of the following apply: * probiotics in the past eight weeks, * antibiotics in the past eight weeks, * pregnancy or lactating women, * medical conditions including short bowel syndrome, celiac disease, biliary disease, pancreatitis, inflammatory bowel disease (crohn's disease, ulcerative colitis), severe cardiovascular, neurological condition, or liver failure, * gastrointestinal surgery within six months of study entry, * history of psychiatric disorder, alcohol or illicit drug abuse.
survey experiment to estimate level of mental illness stigma based on condition and gender

Conditions: Mental Illness; Stigma, Social

Summary: this study aims to measure levels of mental illness stigma based on condition and gender of the participants and individual portrayed with mental illness.

this study aims to measure levels of mental illness stigma based on condition and gender of the participants and individual portrayed with mental illness. this study utilizes eight vignettes portraying different mental illnesses and genders to measure the levels of mental illness stigma in the general community in rural uganda.

Eligibility criteria:
inclusion criteria: * all adults who consider buyende district their primary residence and who are capable of providing consent exclusion criteria: * minors younger than 18 years of age * persons who do not consider buyende district their primary place of residence

Keywords: stigma mental illness low-income country
real-ear measurement (rem) and test box system integration into fitting software

Conditions: Validation Studies

Summary: integration of the rem-verification within the fitting workflow will enable the hearing care professional to easily run real ear measurements. the purpose of the two study parts is to prove that an integrated cooperative system, consisting of fitting software and measurement system, matches desired responses for certain stimuli faster, more reliably and more precisely at the ear drums of hearing instrument wearers than current best practice processes.


Eligibility criteria:
inclusion criteria: * clean and healthy ear canal, eardrum and pinna * ability to keep current position (of head and body) during a period of about 5 minutes while seated. exclusion criteria: * ear infections * ear wax in the ear * hyperacusis * pacemaker * tremor * disability to keep position.
tact-nagoya: therapeutic angiogenesis using cell transplantation

Conditions: Buerger Disease; Arteriosclerosis Obliterans

Summary: clinical studies have established that implantation of bone marrow mononuclear cells (bm-mncs) or peripheral blood mononuclear cells (pb-mncs) into ischaemic limbs increases collateral vessel formation. we, the investigators at nagoya university, further investigated the efficacy and safety of autologous implantation of bm-mncs or pb-mncs in patients with severe ischaemic limbs who have no other alternative therapeutic options. we also examined a potential limiting factor which reduced the efficacy of therapeutic angiogenesis using cell transplantation (tact).


Eligibility criteria:
inclusion criteria: * subjects who have chronic limb ischemia, including rest pain, non-healing ischemic ulcers, or both, and who are not candidates for nonsurgical or surgical revascularisation. exclusion criteria: * poorly controlled diabetes mellitus (hemoglobin a1c \[hba1c\] \> 6.5% and proliferative retinopathy) * evidence of malignant disorder during the past 5 years * subjects who cannot survive more than 1 year with other complications * malignant rheumatic arthritis

Keywords: critical limb ischemia bone marrow mononuclear cells angiogenesis vasculogenesis arteriosclerosis obliterans (aso) ischemic ulcers
vibration training and muscles properties

Conditions: Muscle Relaxation

Summary: application dose standards have not yet been determined for whole body vibration training which is subject to studies with different frequencies and amplitudes. our objective was to examine acute responses of two different vibration training doses on muscle tone, strength, and flexibility.

application dose standards have not yet been determined for whole body vibration training which is subject to studies with different frequencies and amplitudes. our objective was to examine acute responses of two different vibration training doses on muscle tone, strength, and flexibility.

Eligibility criteria:
inclusion criteria: * healthy and untrained participants. * dominant side of the participants was recorded and only right dominant individuals were included. exclusion criteria: * participants with body weight over 120 kg. * participants had lower extremity trauma and lower extremity movement restriction. * participants who had any cardiovascular or neurological conditions, dizziness or vertigo

Keywords: muscle power, muscle flexibility, muscle tone, whole-body vibration training.
a phase ⅲ randomized clinical trial of postmastectomy hypofractionation radiotherapy in high-risk breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to compare the efficacy and toxicities of hypofractionation radiotherapy with conventional fractionation radiotherapy in breast cancer patients treated with mastectomy.it is hypothesized that the efficacy and toxicities are similar between the two groups.

eligible breast cancer patients with mastectomy and axillary dissection are randomized into 2 groups:conventional fractionation radiotherapy of 50 gy in 25 fractions within 5 weeks to ipsilateral chest wall and supraclavicular nodal region,and hypofractionation radiotherapy of 43.5gy in 15 fractions within 3 weeks to the same region. during and after radiotherapy, the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.

Eligibility criteria:
inclusion criteria: * ipsilateral histologically confirmed invasive breast cancer * undergone total mastectomy and axillary dissection * t3-4,or \>=4 positive axillary lymph nodes * fit for chemotherapy(if indicated),endocrine therapy(if indicated)and postoperative irradiation * written,informed consent * ct3-4,or cn2, or pathological positive axillary lymph nodes during mastectomy for patients who had received neoadjuvant chemotherapy or hormone therapy * no supraclavicular or internal mammary nodes metastases * no distant metastases * enrollment date no more than 8 months after surgery or no more than 2 months after chemotherapy for patients who didn't receive neoadjuvant systemic therapy. * enrollment date no more than 2 months after surgery for patients who had received neoadjuvant systemic therapy and didn't need adjuvant chemotherapy. exclusion criteria: * patients who undergone previous irradiation to the ipsilateral chest wall and supraclavicular region * previous or concurrent malignant other than non-melanomatous skin cancer * unable or unwilling to give informed consent * bilateral breast cancer * immediate or delayed ipsilateral breast cancer reconstruction

Keywords: breast cancer mastectomy radiotherapy fractionation
a study of niraparib in patients with ovarian cancer in clinical practice

Conditions: Ovarian Cancer

Summary: the main aim of this study is to check for side effects from treatment with niraparib. the study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. during the study, participants with ovarian cancer will take capsules of niraparib (zedula) once a day according to their clinic's standard practice. the study doctors will check for side effects from niraparib for 1 year after treatment starts.


Eligibility criteria:
inclusion criteria: an individual who corresponds to any of the following: * ovarian cancer patients after initial chemotherapy (maintenance therapy) * patients with platinum antineoplastic drug sensitive recurrent ovarian cancer (maintenance therapy) * recurrent ovarian cancer with platinum-sensitive homologous recombination repair defects. exclusion criteria: has a history of hypersensitivity to any of the ingredients of this drug.
study to identify and describe predictive factors for thromboembolic events in patients with high-risk polycythemia vera

Conditions: Polycythemia Vera

Summary: this is a prospective observational study that will enroll patients with high-risk polycythemia vera (pv) with at least one thromboembolic event (te) after diagnosis or up to 2 years prior to diagnosis. this is a non-randomized study, and to ensure a sufficient number of patients in both cohorts, enrollment in each cohort will be terminated once the target of 150 patients has been reached.

all patients are already on treatment with hydroxyurea or ruxolitinib at enrollment as per clinical practice and independently of their participation in this study. in addition, the follow-up visits and the evaluation procedures required in the study protocol correspond to current clinical practice. according to local regulations related to observational studies, assessments such as blood tests are justified by the purpose and rationale of the study (i.e., the identification of possible predictive factors of tes) and are considered current clinical practice. data related to other procedures will be collected only if such procedures are performed as per clinical practice but are not required otherwise. patients in both cohorts will be followed for 3 years after enrollment and will have visits at months 6, 12, 18, 24, 30 and 36. a time window of ± 1 month is permitted for all visits.

Eligibility criteria:
inclusion criteria: 1. signed informed consent must be obtained prior to participation in the study. 2. age ≥18 years. 3. diagnosis of pv according to who 2008 or who 2016 and high-risk stratification according to european leukemianet (eln) classification. 4. at least one te after diagnosis or up to 2 years prior to diagnosis. 5. patients on treatment with hydroxyurea at enrollment and for at least 18 months prior to enrollment or those on treatment with ruxolitinib who started treatment up to 18 months before enrollment.

Keywords: polycythemia vera high-risk polycythemia vera pv ruxolitinib nis italy te predictive factors hydroxyurea
the use of tolvaptan to prevent renal dysfunction in high risk patients with heart failure-pilot study

Conditions: Heart Failure

Summary: it is well known that the use of loop diuretics in acute setting may decrease glomerular filtration rate (gfr) and increase serum creatinine leading to renal dysfunction. loop diuretic induced elevation in serum creatinine can lead to increase in length of hospital stay and possibly morbidity. previous studies have suggested that tolvaptan unlike aggressive loop diuretic therapy may not activate neurohormonal system nor decrease renal blood flow. these properties may make tolvaptan a useful addition to diuretic therapy to prevent renal dysfunction in high-risk patients. therefore the primary objective of this study is to determine if the use of tolvaptan in combination with diuretic therapy may prevent development of renal dysfunction in high risk patients with heart failure. hypothesis: administration of tolvaptan in combination with continuous loop diuretic therapy in acutely decompensated heart failure patients at high risk for developing diuretic induced renal dysfunction will have a lower proportion of patients increasing their serum creatinine \> 0.3 mg/dl within a 96 hour time frame as compared to patients just receiving standard of care continuous infusion diuretic.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old * prior clinical diagnosis of systolic heart failure (ef \< 40% within the past 18 months) with daily home use of oral loop diuretic for at least one month. * daily oral dose of furosemide ≥ 40 mg and ≤ 240 mg (or equivalent) * identified within 24 hours of hospital admission * heart failure defined by at least 1 symptom (dyspnea, orthopnea, or edema) and 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular congestion on chest radiography) * anticipated need for iv loop diuretics for at least 48 hours * likely requires daily net urine output in the range of 1-3 l/day for over a 72-96 hour time period. * albumin level \< 3.5 g/dl * willingness to provide informed consent exclusion criteria: * received or planned iv vasoactive treatment (inotropes, vasodilators) or ultra-filtration therapy for heart failure * bnp \< 250 ng/ml or nt-probnp \< 1000 mg/ml (if drawn for clinical purposes) * systolic bp \< 90 mmhg * serum creatinine \> 3.0 mg/dl at baseline or renal replacement therapy or creatinine clearances \< 10 ml/min * serum sodium \> 145 meq/l * acute coronary syndrome within 4 weeks * anticipated need for coronary angiography or other procedures requiring iv contrast. * patients receiving any of the following drugs: clarithromycin, ketoconazole, itraconazole,ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, telithromycin, erythromycin, fluconazole, aprepitant, diltiazem, verapamil, cyclosporine, and grapefruit juice. * pregnant or nursing patients.
atrial fibrillation: risk and benefits of anti-coagulation in the elderly

Conditions: Anticoagulants Causing Adverse Effects in Therapeutic Use; Atrial Fibrillation; Frail Elderly Syndrome

Summary: this study was designed to assess the effectiveness of oral anticoagulants in elderly patients (\>=75 years) with atrial fibrillation. all patients discharged from one large hospital in stockholm, danderyds hospital, between november 1st 2010 and december 31st 2017 with atrial fibrillation as main diagnosis have been included (n=2943). adverse events (cardiovascular death, fatal/non fatal ischemic stroke, peripheral thromboembolism, fatal/non fatal intracerebral hemorrhage and extracranial bleeding) are recorded through linkage to mandatory and qualitative national registries and review of the medical records until december 31 2018.

the investigators established a prospective cohort of 2943 of elderly (\>=75 years old) discharged with atrial fibrillation as main diagnosis from november 1st 2010 to december 31st 2017 from a large hospital in the northern part of stockholm in sweden, danderyds hospital. atrial fibrillation diagnosis is defined by the (icd-10) codes: i48.0-i48.9 (atrial fibrillation and atrial flutter) according to the international classification of diseases, 10th revision. the first admission to the hospital during the study period is recorded as the index admission. clinical and anamnestic data, anthropometric measures, biochemical data, treatment at admission and at discharge have been recorded for each patient through the screening of medical journals.

Eligibility criteria:
inclusion criteria: • all consecutive patients discharged with atrial fibrillation as main diagnosis from danderyds hospital from november 1st 2011 to december 31 2017 aged 75 years or more. exclusion criteria: * patients who have not given their consensus to the use of medical journals for register based research. * patients who were discharged from the hospital with atrial fibrillation as main diagnosis but were admitted to the hospital for medical reasons unrelated to atrial fibrillation (as an example change of pacemakers batteries). * patients whose medical records are not consistent with the main diagnosis (as an example wrong icd code).
gallium-68 psma-11 pet in participants with prostate cancer

Conditions: Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8

Summary: this phase ii trial studies how well gallium-68 psma-11 pet/ct or pet/mri works in finding prostate cancer cells that have come back (recurrent) in patients with prostate cancer. gallium-68 psma-11 is a type of radioactive compound, called a radiotracer, which is injected in the vein and can accumulate in tumor cells to generate a signal detected by pet/ct or pet/mri imaging. this may help researchers in finding recurrent prostate cancer cells in patients with prostate cancer.

primary objective: i. to assess the positive predictive value (ppv) of gallium ga 68-labeled psma-11 (68ga-psma11) positron emission tomography/computed tomography (pet/ct) and positron emission tomography/magnetic resonance imaging (pet/mri) on a patient level using histopathology or confirmatory imaging as a standard of truth (sot). secondary objectives: i. to assess the ppv per-patient for 68ga-psma-11 pet/ct and pet/mri detection of tumor location confirmed by histopathology/biopsy alone. ii. demonstrate the safety of 68ga-psma-11 pet/ct or pet/mri imaging in participants with prostate cancer. iii. demonstrate the efficacy of 68ga-psma-11 pet/ct or pet/mri imaging to monitor response to treatment in participants with prostate cancer. outline: patients receive gallium 68ga-psma-11 intravenously (iv). 50-100 minutes after injection, patients then undergo a pet/ct scan or pet/mri scan over 60 minutes. after completion of study, patients are followed up at 30 and 90 days, then between 3-36 months.

Eligibility criteria:
inclusion criteria: * pathologically proven prostate cancer * rising prostate-specific antigen (psa) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy) * karnofsky performance status (kps) \>= 50 (eastern cooperative oncology group \[ecog\]/world health organization \[who\] 0, 1, or 2) * ability to understand and willingness to provide informed consent * participants with known metastatic prostate cancer planned to undergo active systemic treatment exclusion criteria: * unable to lie flat, still, or tolerate a pet or mri scan * contraindication to optional furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs. this exclusion criteria can be removed if furosemide is omitted as part of the pet imaging protocol if a second-generation scatter correction - (defined as either ga-68 specific prompt gamma correction or multiple scatter model) is available for the used pet device